利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.018 秒)

    NOUVELLES LECTINES ET APPLICATIONS POUR LA DÉTECTION DE MARQUEURS D'ÉTATS PATHOLOGIQUES
    1.
    发明公开
    NOUVELLES LECTINES ET APPLICATIONS POUR LA DÉTECTION DE MARQUEURS D'ÉTATS PATHOLOGIQUES 审中-公开
    新型凝集素和应用用于检测标志物病理学

    公开(公告)号：EP3114487A1

    公开(公告)日：2017-01-11

    申请号：EP15711300.2

    申请日：2015-02-26

    申请人： Centre National de la Recherche Scientifique CNRS ,  Université Joseph Fourier

    发明人： IMBERTY, Anne ,  AUDFRAY, Aymeric ,  ARNAUD, Julie

    IPC分类号： G01N33/68 ,  A61K49/14 ,  A23J3/20

    CPC分类号： G01N33/68 ,  C07K14/4726 ,  G01N2333/4724 ,  G01N2440/38 ,  G01N2570/00

    摘要： Multimenic lectins having a β-propeller architecture, formed from monomer modules of approximately 30 to 60 amino acids, in which the binding sites to the glycans are situated on a given side of the proteins and the O-terminus and N-terminus ends of the peptide chains on the other side of the proteins, characterized in that they are formed from 4 to 7 monomer modules, a single, or a plurality of, or all of the adjacent modules being linked to one another by the linkers linking the N-terminus end of one module to the C-terminus end of the adjacent module.

    摘要翻译： 作为具有β螺旋桨结构，从大约30至60个氨基酸，其中该结合位点的聚糖都位于蛋白和O末端和N-末端的给定侧的单体模块构成Multimenic凝集素的结束 对蛋白质的另一侧的肽链，在thatthey特点是从4到7的单体模块，单个或多个形成，或所有相邻的模块被彼此连接由连接器连接的N末端 一个模块的相邻模块的C末端端的一端。

    GLYCOMIMETIC COMPOUNDS AS ANTI-INFECTIOUS AGAINST PATHOGENS LECTINS
    4.
    发明公开
    GLYCOMIMETIC COMPOUNDS AS ANTI-INFECTIOUS AGAINST PATHOGENS LECTINS 有权
    GLYCOMIMETISCHE化合物作为防抗致病性凝集素

    公开(公告)号：EP2649085A1

    公开(公告)日：2013-10-16

    申请号：EP10812804.2

    申请日：2010-12-10

    申请人： Centre National de la Recherche Scientifique CNRS ,  Université Claude Bernard Lyon 1

    发明人： IMBERTY, Anne ,  VIDAL, Sébastien ,  MATTHEWS, Susan ,  FAURE, Karine ,  GUERY, Benoit ,  CECIONI, Samy

    IPC分类号： C07H3/06 ,  C07H5/06 ,  A61K31/7028 ,  A61P31/04

    CPC分类号： C07H17/08 ,  C07H3/06 ,  C07H5/06 ,  C07H17/02

    摘要： The present invention relates to a calixarene-based glycosylated compound (I) having the formula : (I) wherein D is independently selected in the group comprising a –CH
    2 –group, an oxygen atom, a sulphur atom, a sulfinyl group or a sulfonyl group, E is independently selected in the group comprising a hydrogen, an alkyl having from 1 to 10 carbon atoms, an aryl having from 6 to 20 carbon atoms, a nitrogen dioxide group, an azide group, an amino group, a guanidinium group,a halogen atom, a –CH
    2 R group wherein R is a hydroxyl, a halogen, an amino group, a N(alkyl)
    2 group, a NH(alkyl) group, or E represents a –CO-R' wherein R' is a hydrogen atom, a hydroxyl group or an amino, B represents a A–C group wherein A is independently selected in the group comprising an oxygen atom, a sulfur atom, a NH group or a (CH
    2 )
    i group, i being an integer from 1 to 10, C is independently selected in the group comprising a hydrogen, an alkyl, an alkenyl, an alkynyl, or C is a group of formula (II). The present invention also relates to a pharmaceutical composition characterized in that it comprises the said calixarene-based glycosylated compound (I), in combination with pharmaceutically acceptable carriers or diluents. The present invention also relates to the use of the said calixarene-based glycosylated compound (I) or the said pharmaceutical composition, for the manufacture of a drug intended to prevent or treat bacterial infections from pathogens that use lectins in the first steps of infection.